Skip to content

Clinical trials

Completed Carcinoma, Squamous Cell trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Squamous Cell Status: Completed Country / region: United States Clear all

149 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20024
20032
20043
20055
20069
20079
20086
200913
20109
20116
20127
20135
201412
20154
20167
201710
20188
20199
20204
20211
20221
20234
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed149

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Memorial Sloan Kettering Cancer Center10
H. Lee Moffitt Cancer Center and Research Institute7
M.D. Anderson Cancer Center7
National Cancer Institute (NCI)5
UNC Lineberger Comprehensive Cancer Center5
Dana-Farber Cancer Institute4
Northwestern University4
Abramson Cancer Center at Penn Medicine3
Mayo Clinic3
Stanford University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Squamous Cell149
Head and Neck Neoplasms54
Squamous Cell Carcinoma of Head and Neck37
Basal Cell Carcinoma25
Carcinoma, Non-Small-Cell Lung21
Melanoma20
Skin Neoplasms18
Lung Neoplasms16
Adenocarcinoma14
Oropharyngeal Neoplasms12

Trials

Showing 1 to 25 of 149. Each trial links to its page on Pharma Observatory.

49 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.